USPTO serial 97117501
PRECISION BIOSCIENCES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 25, 2023
- Examiner
- BUSH, KAREN K
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PRECISION BIOSCIENCES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Eva Gullick Frongello
Eva Gullick Frongello Parker Poe Adams & Bernstein LLP301 Fayetteville Street, Suite 1400Raleigh, NC 27601UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | genome editing reagents for research purposes; Chemical, biochemical, biotechnological products intended for industry, agriculture, horticulture, namely, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely, polypeptides for in vivo and in vitro genetic engineering; Biochemicals and biologics, namely, engineered proteins for gene regulation, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, gene modification, and gene correction, all for use in scientific research, pharmaceutical research, agricultural biotechnology, diagnostics, and industrial biotechnology; engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for use in scientific research and analysis and diagno | ACTIVE | Feb 11, 2008 |
| 005 | pharmaceutical preparations, namely, cell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cells, namely, genetically modified immune cells for use in human therapeutics and in the treatment of cancer; pharmaceutical and biological preparations based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in human therapeutics, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations; engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use | ACTIVE | Feb 25, 2016 |
| 042 | research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic disease, gene therapy and cell therapy; pharmaceutical research and development services; Scientific research; scientific research in genetic, medical, pharmaceutical and veterinary fields; scientific research in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis in the field of immunotherapy; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer | ACTIVE | Feb 11, 2008 |
| 044 | Medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating disease, namely, the treatment of cancer | ACTIVE | Feb 25, 2016 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Precision BioSciences, Inc.
- Other trademarks owned by Precision BioSciences, Inc.
- Other trademarks owned by Precision BioSciences, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PRECISION BIOSCIENCES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 8, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 8, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 8, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 8, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 8, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 25, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 25, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 6, 2023 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Mar 6, 2023 | LOPR | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN | — |
| Mar 6, 2023 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Mar 1, 2023 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Jan 18, 2023 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Dec 20, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 20, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 15, 2022 | LOPT | LETTER OF PROTEST EVIDENCE FORWARDED | — |
| Nov 30, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 17, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 2, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 2, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 2, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 12, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 12, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 12, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 10, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 17, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 13, 2021 | NWAP | NEW APPLICATION ENTERED | — |